What does this research mean for the field?

Approximately 90% of migraine patients in Japan who are eligible for calcitonin gene-related peptide monoclonal antibodies (CGRP mAbs) have never received the therapy, highlighting a substantial treatment gap driven by low awareness and limited specialist access. Novelty: ClaimNovelty.INCREMENTAL. Consensus alignment: ConsensusAlignment.NEUTRAL.

What question did this study set out to answer?

This analysis aims to evaluate the utilization patterns of CGRP monoclonal antibodies in Japan and identify treatment gaps among migraine patients.

July 26, 2026Drugs - Real World OutcomesOpen Access

Calcitonin Gene-Related Peptide Monoclonal Antibody Utilization and Treatment Gaps in People with Migraine in Japan: Results from the OVERCOME (Japan) 2nd Study

View Full Paper

Ask AI

Bookmark

Authors

YHY HanaokaMiyazaki Welfare Medical College TTTsubasa TakizawaKeio University RIRyotaro IshiiKyoto Prefectural University of Medicine

Discussion

Member takes

Implication

Observational survey evaluates CGRP mAb utilization and treatment gaps in migraine patients, indicating significant improvement needs.

Key Points

This analysis aims to evaluate the utilization patterns of CGRP monoclonal antibodies in Japan and identify treatment gaps among migraine patients.
Nationwide, population-based, cross-sectional online survey
Included 19,590 respondents with migraine, classified by CGRP mAb eligibility
Multivariate logistic regression to identify factors related to CGRP mAb treatment experience
Only 7.6% of respondents were CGRP mAb eligible, with about 90% never having received treatment.
Low awareness of CGRP mAbs among eligible nonusers, with 78% unaware of treatments.
CGRP mAb treatment experience was significantly associated with prior triptan use (OR 9.38) and consultations at prescribing departments (OR 7.20).

Cite This Study

Hanaoka et al. (2026) studied this question.

synapsesocial.com/papers/6a65a49fd3aea3239cd7730c https://doi.org/10.1007/s40801-026-00571-9

View Full Paper

Ask AI

Bookmark

Calcitonin Gene-Related Peptide Monoclonal Antibody Utilization and Treatment Gaps in People with Migraine in Japan: Results from the OVERCOME (Japan) 2nd Study

Discussion

Member takes

Implication

Key Points

Cite This Study

Calcitonin Gene-Related Peptide Monoclonal Antibody Utilization and Treatment Gaps in People with Migraine in Japan: Results from the OVERCOME (Japan) 2nd Study

Discussion

Member takes

Implication

Key Points

Cite This Study

Also Consider

Also Consider